company background image
PYC logo

PYC Therapeutics ASX:PYC Stock Report

Last Price

AU$0.10

Market Cap

AU$466.6m

7D

5.0%

1Y

90.9%

Updated

13 Jun, 2024

Data

Company Financials +

PYC Therapeutics Limited

ASX:PYC Stock Report

Market Cap: AU$466.6m

PYC Stock Overview

A drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia.

PYC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PYC Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PYC Therapeutics
Historical stock prices
Current Share PriceAU$0.10
52 Week HighAU$0.13
52 Week LowAU$0.052
Beta0.62
1 Month Change5.00%
3 Month Change23.53%
1 Year Change90.91%
3 Year Change-32.26%
5 Year Change303.85%
Change since IPO-59.62%

Recent News & Updates

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

Apr 10
Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

Recent updates

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

Apr 10
Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?

Nov 10
Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?

We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully

Jul 03
We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully

Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

Jan 25
Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

Jul 31
Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate

Mar 28
We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Feb 20
Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

Jan 26
Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

Dec 22
What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

Nov 17
We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

Shareholder Returns

PYCAU BiotechsAU Market
7D5.0%-1.5%-0.7%
1Y90.9%-0.5%8.2%

Return vs Industry: PYC exceeded the Australian Biotechs industry which returned -0.5% over the past year.

Return vs Market: PYC exceeded the Australian Market which returned 8.2% over the past year.

Price Volatility

Is PYC's price volatile compared to industry and market?
PYC volatility
PYC Average Weekly Movement11.5%
Biotechs Industry Average Movement11.4%
Market Average Movement8.7%
10% most volatile stocks in AU Market16.5%
10% least volatile stocks in AU Market3.2%

Stable Share Price: PYC's share price has been volatile over the past 3 months.

Volatility Over Time: PYC's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aRohan Hockingspyctx.com

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. The company’s preclinical development programs include VP-001, a drug program for retinitis pigmentosa type 11; PYC-001, a drug program for the treatment of autosomal dominant optic atrophy; and PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases.

PYC Therapeutics Limited Fundamentals Summary

How do PYC Therapeutics's earnings and revenue compare to its market cap?
PYC fundamental statistics
Market capAU$466.61m
Earnings (TTM)-AU$21.65m
Revenue (TTM)AU$21.24m

23.1x

P/S Ratio

-22.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PYC income statement (TTM)
RevenueAU$21.24m
Cost of RevenueAU$0
Gross ProfitAU$21.24m
Other ExpensesAU$42.89m
Earnings-AU$21.65m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0046
Gross Margin100.00%
Net Profit Margin-101.90%
Debt/Equity Ratio0%

How did PYC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.